Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Inmune Bio, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 34 | 37 | +3 |
| Shares | 2.19M | 2.14M | −52.5K (−2.4%) |
| Value | $18.2M | $14.5M | −$3.73M (−20.5%) |
New holders (7)
Institutions that held Inmune Bio, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Fermata Advisors, LLC | 56,702 | $383.9K | 0.11% |
| Bank of New York Mellon Corp | 32,891 | $222.7K | 0.00% |
| Squarepoint Ops LLC | 10,308 | $70.5K | 0.00% |
| Beacon Pointe Advisors, LLC | 10,368 | $70.2K | 0.00% |
| LPL Financial LLC | 10,097 | $68.4K | 0.00% |
| GWM Advisors LLC | 5,425 | $36.7K | 0.00% |
| NBC Securities, Inc. | 270 | $1.00K | 0.00% |
Sold out (4)
Institutions that held Inmune Bio, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Millennium Management LLC | 28,146 | $255.6K |
| Renaissance Technologies LLC | 20,000 | $182.0K |
| FNY Investment Advisers, LLC | 100 | $0 |
| Meitav Dash Investments Ltd | 181,140 | – |